(Q43224166)

English

Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

immunosuppression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

U E Lang

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

J Heger

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

M Willbring

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

M Domula

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

K Matschke

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

S M Tugtekin

6

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

4285-4288

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Reversible symmetric polyneuropathy with paraplegia after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Cyclosporine-associated neurotoxicity. The need for a better guide for immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Drug Therapy in the Heart Transplant Recipient: Part I: Cardiac Rejection and Immunosuppressive Drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Severe central-nervous-system toxicity associated with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Cyclosporine-associated encephalopathy: a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Calcineurin inhibitors in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Hypertension in heart and heart-lung transplanted children: does impaired baroreceptor function play a role?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Conversion from cyclosporine to sirolimus in stable renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Clinical experience with everolimus (Certican) in young renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Clinical experience with everolimus (Certican) in elderly recipients: the "old-for-old" concept

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Optimizing the immunosuppressive regimen in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

mTOR signaling in the hippocampus is necessary for memory formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-Mammalian target of rapamycin pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Association of a functional BDNF polymorphism and anxiety-related personality traits

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.050

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2009.08.050

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43224166&oldid=1984161513"